Urinary Albumin Levels are Independently Associated with Renal Lesion Severity in Patients with Lupus Nephritis and Little or No Proteinuria

Jin Ding, Zhaohui Zheng, Xueyi Li, Yuan Feng, Nan Leng, Zhenbiao Wu, Ping Zhu

Background: Systemic lupus erythematosus (SLE) leads to renal lesions, which may be clinically silent in patients with little or no proteinuria. Early detection of these lesions may improve prognosis, but early markers are controversial. This study aimed to determine renal marker proteins associated with renal lesion severity in patients with lupus nephropathy (LN) and little or no proteinuria.

Material/Methods: Patients with LN and little or no proteinuria (<0.5 g/24 hours) (n=187) that underwent kidney biopsy were grouped according to: low severity (Class I or II; n=116) versus high severity (Class III, IV, or V; n=71). Disease status was determined according to the SLE disease activity index (SLEDAI). Renal marker proteins (serum β2-macroglobulin, urinary β2-macroglobulin, albumin, IgG, and α1-macroglobulin) were measured using radioimmunoassay.

Results: Compared with the low severity group, patients in the high severity group had higher urinary albumin (11.60±8.94 versus 7.08±10.07 µg/mL, p=0.008) and urinary IgG (13.21±9.35 versus 8.74±8.90 µg/mL, p=0.007) levels. Multivariate conditional logistic regression analysis showed that urinary albumin (odds ratio (OR)=1.417, 95% confidence interval (95% CI): 1.145–1.895, p=0.001) and SLEDAI (OR=2.004, 95% CI: 1.264–3.178, p=0.003) were independently associated with severe renal lesions in these patients. Using an optimal cutoff point of urinary albumin of 7.53 µg/mL resulted in 67% sensitivity and 82% specificity for the detection of high severity renal lesions.

Conclusions: Urinary albumin levels and SLEDAI were independently associated with histological severity of renal lesions in patients with LN and little or no proteinuria. These parameters could be used to help select patients for renal biopsy.

MeSH Keywords: Acute Kidney Injury • Lupus Nephritis • Proteinuria

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/899973
Background

Lupus nephritis (LN) occurs in 40–70% of patients with systemic lupus erythematosus (SLE) and is among the most serious complications of SLE [1]. The incidence of LN is higher in Asians (55%) compared with Caucasians (14%) [1,2]. In China, LN is the most common renal disease and accounts for 54.3% of all secondary glomerular diseases [3]. The manifestations of LN range from asymptomatic urinary findings to nephrotic syndrome and progressive renal impairment. The International Society of Nephrology and the Renal Pathology Society (ISN/RPS) have indicated that the various LN classes exhibit different natural history and clinical patterns [4]. ISN/RPS Classes I and II usually display low activity and chronicity index, and have an indolent course. On the other hand, Classes III, IV, and V are progressive types of LN [5]. For Class IV, the 5-year probability of developing end-stage renal disease (ESRD) is as high as 70% [6]. Early and accurate detection of kidney involvement is needed to improve the prognosis of patients with LN.

Generally, urinalysis is the most effective method for detecting and monitoring LN disease severity by assessing the dominant feature of LN, i.e., proteinuria [7], but previous studies casted doubts on the ability of urinary findings to predict the underlying presence and severity of nephritis, at least at the early stage [8–12]. In addition, some patients may have significant kidney damage and still be asymptomatic, at least based on conventional urine disease markers [13,14]. Renal biopsy is required for diagnosing LN and planning therapy, but this approach is invasive and a biopsy is ethically acceptable only for patients with at least a suspicion of LN [6]. Furthermore, studies have suggested that significant kidney damage (Class III, IV, or V) may be present in many patients with SLE, but without any sign of renal involvement, i.e., in the presence of little or no proteinuria (<0.5 g/24 hours) [5,15,16].

In asymptomatic patients, the total amount of urine protein may be small, but some specific proteins could predict or indicate kidney damage. Indeed, proteins of high molecular weight such as IgG (150 kD) are excreted in large quantities under normal conditions and served as immunoglobulins with regulatory immunity. As renal disease progresses, the amount of IgG excretion increases. Furthermore, proteins (serum 1-MG >5 µg/mL; 2) hypocomplementemia (C3 <79 mg/dL and/or C4 <16 mg/dL), and/or 3) positive anti-double stranded DNA (dsDNA) and/or positive anti-nucleosome antibodies [27,28].

Histological renal tissue subtypes (Classes I-VI) were determined according to the 2003 ISN/RPS LN classification [4]. LN patients with little or no proteinuria (n=187) were divided into two groups: low severity (Classes I and II LN) (group 1) and high severity (Classes III, IV, and V) (group 2), according to a previous report [5].

The demographic characteristics and clinical manifestations of the 187 patients with LN and little or no proteinuria are controversial and additional studies are still necessary to address their value for the early detection of LN.

Therefore, the present study aimed to find renal marker proteins that could be associated with renal histopathological findings, in order to provide bases for early diagnosis of LN in patients with little or no proteinuria.

Material and Methods

Patients

This study was approved by the ethics committee of the Xijing Hospital, Fourth Military Medical University (Xi’an, China) (No. 20110303-6). Written informed consent was obtained from each participant.

The study included 187 patients with LN and little or no proteinuria (as based on previous studies, <0.5 g/24 hours) that underwent kidney biopsy at the Department of Clinical Immunology of Xijing Hospital between April 2005 and November 2010. Inclusion criteria were: 1) all patients were confirmed with LN by biopsy and fulfilled the 1982 American College of Rheumatology (ACR) revised criteria for SLE [26]; and 2) little or no proteinuria (<0.5 g/24 hours). Patients with renal failure and serum creatinine levels >2 mg/dL were excluded.

Indications for renal biopsy include patients with low or no proteinuria (<0.5 g/24 hours) and with or without hematuria (urinary red blood cell count >25/µL), pyuria (urinary white blood cell count >25/µL), or accompanied by: 1) abnormal increase of renal marker proteins (serum β2-MG >3 µg/mL, β2-MG >160 ng/mL, urinary albumin >6 µg/mL, urinary IgG >5.5 µg/mL, or urinary α1-MG >5 µg/mL); 2) hypocomplementemia (C3 <79 mg/dL and/or C4 <16 mg/dL), and/or 3) positive anti-double stranded DNA (dsDNA) and/or positive anti-nucleosome antibodies [27,28].
Table 1. General characteristics and clinical manifestations in LN patients with little or no proteinuria according to histologic classification of kidney biopsies.

| Variables                          | Low severity (Classes I and II) | High severity (Classes III, IV, and V) | p       |
|-----------------------------------|---------------------------------|--------------------------------------|---------|
| Female, n (%)                     | 110 (94.8)                      | 62 (87.3)                            | 0.067   |
| Age at onset (years)              | 30.9±10.6                       | 29.3±9.9                             | 0.402   |
| Disease duration (months)         | 42.3±50.4                       | 50.6±60.1                            | 0.410   |
| Time between symptom onset and SLE diagnosis (months) | 32.8±48.6                      | 24.6±14.6                            | 0.331   |
| Time between LN onset and LN diagnosis (months) | 4.7±13.5                        | 8.8±17.1                             | 0.148   |
| Fever, n (%)                      | 54 (46.6)                       | 44 (62.0)                            | 0.040*  |
| Malar rash, n (%)                 | 50 (43.1)                       | 37 (52.1)                            | 0.231   |
| Photosensitivity, n (%)           | 34 (29.3)                       | 14 (19.7)                            | 0.145   |
| Oral ulcers, n (%)                | 21 (18.1)                       | 22 (31.0)                            | 0.042*  |
| Alopecia, n (%)                   | 70 (60.3)                       | 44 (62.0)                            | 0.825   |
| Raynaud phenomenon, n (%)         | 47 (40.5)                       | 21 (29.6)                            | 0.131   |
| Arthritis, n (%)                  | 89 (76.7)                       | 56 (78.9)                            | 0.733   |
| Serositis, n (%)                  | 23 (19.8)                       | 16 (22.5)                            | 0.658   |
| Myositis, n (%)                   | 18 (15.5)                       | 9 (12.7)                             | 0.592   |
| Neurological disorder, n (%)      | 8 (6.9)                         | 8 (11.3)                             | 0.300   |
| Leucopenia, n (%)                 | 56 (48.3)                       | 31 (43.7)                            | 0.539   |
| Anemia, n (%)                     | 39 (33.6)                       | 29 (40.8)                            | 0.219   |
| Thrombocytopenia, n (%)           | 20 (17.2)                       | 26 (36.6)                            | 0.003** |
| Hypertension, n (%)               | 12 (10.3)                       | 20 (28.2)                            | 0.002** |
| SLEDAI                           | 7.7±6.5                         | 12.5±6.6                             | <0.001*** |
| C3 (mg/dl)                        | 72.3±30.9                       | 58.0±28.3                            | 0.003   |
| Low C3, n (%)                     | 59 (50.9)                       | 59 (83.1)                            | <0.001*** |
| C4 (mg/dl)                        | 14.5±12.1                       | 11.6±8.9                             | 0.150   |
| Low C4, n (%)                     | 62 (53.4)                       | 51 (71.8)                            | 0.014*  |
| Proteinuria                       |                                |                                      |         |
| ≤0.3 g/24 h, n (%)                | 98 (84.5)                       | 52 (73.2)                            | 0.088   |
| 0.3–0.5 g/24 h, n (%)             | 18 (15.5)                       | 19 (26.8)                            |         |
| Hematuria (%)                     | 15 (12.9)                       | 25 (35.2)                            | <0.001*** |
| Pyuria (%)                        | 10 (8.6)                        | 13 (18.3)                            | <0.001*** |
| ANA (positive), n (%)             | 112 (96.6)                      | 67 (94.4)                            | 0.474   |
| Anti-dsDNA (positive), n (%)      | 47 (40.5)                       | 42 (59.2)                            | 0.016*  |
| Anti-Sm (positive), n (%)         | 29 (25.0)                       | 17 (23.9)                            | 0.871   |

© Med Sci Monit, 2017; 23: 631-639

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
160 (85.6%) patients had disease onset between 16–50 years old, 21 (11.2%) patients had pediatric onset (<16 years), and six (3.2%) patients had late onset (>50 years).

Data collection and measurements

Disease status was determined using the SLE disease activity index (SLEDAI) [29]. Patients with a SLEDAI >10 were considered to have highly active disease. The clinical data included demographics, disease duration, clinical manifestations, immunological measurements, and treatments, all collected from the medical records. Urine and blood samples were routinely obtained at the same time as the renal biopsies. Serum antinuclear antibodies were measured by indirect immunofluorescence on mitotic Hep-2 cells (MBL, Nagoya, Japan). Serum anti-dsDNA antibodies were measured by indirect immunofluorescence assays (EUROIMMUN. AG, Germany). Serum anti-Sm, anti-RNP antibodies, anti-SSA antibodies, anti-SSB antibodies, and antinucleosome were detected using dot blot assays (EUROIMMUN. AG, Germany). C3 and C4 were determined by nephelometry (Bio-red, Beckman Array 360 System, Miami, USA), and hypocomplementemia was defined as C3 <79 mg/dL and/or C4 <16 mg/dL.

Renal biopsy specimen

Percutaneous renal biopsies were performed under local anesthesia in the left renal pole under ultrasound guidance using automatic 16 gauge needles (Angiotech Surgical Specialties Corp., Wyomissing, PA, USA). Renal biopsy specimens were evaluated by light microscopy (H&E staining, Masson trichrome staining, periodic acid-Schiff staining, and metemahicine silver staining), immunofluorescence (IgG, IgA, IgM, C3, and C4 levels), and electron microscopy (ultrastructural changes). Histological renal tissue subtypes were determined according to the 2003 ISN/RPS LN classification [4]. Renal biopsies were analyzed and independently reclassified (Classes I-V) by two renal pathologists and grouped as above (low versus high severity). Activity and chronicity indexes (AI and CI, respectively) were estimated according to previously reported criteria [30]. No serious complication was detected in any patient after renal biopsy.

Statistical analysis

All data were analyzed using SPSS 13.0 (SPSS Inc., Chicago, IL, USA). Continuous variables are expressed as means±standard deviation (SD) and were analyzed using the independent sample t-test. Categorical variables are expressed as proportions and were compared using the chi-square or the Fisher’s exact test, as appropriate. Associations between renal marker proteins and histologic classification of kidney biopsies (Classes I and II versus Classes III, IV, and V) were examined by multivariate conditional logistic regression models using the backward stepwise method, including variables that were significantly associated (p<0.05) in univariate analyses; UAL and urine IgG were treated as continuous variables, while the others were...
Table 2. Renal biopsy findings in 187 Lupus Nephritis (LN) patients with little or no proteinuria.

| Class         | I   | II  | III | IV  | V   | VI  |
|---------------|-----|-----|-----|-----|-----|-----|
| N (%)         | 5   | 111 | 30  | 172 | 9   | 0   |
| Activity index| –   | 2.57±0.97 | 4.96±2.08 | 8.37±3.03 | 3.73±2.43 | –   |
| Chronicity index | –   | 1.35±1.19 | 2.75±1.46*** | 3.18±1.80*** | 2.54±1.99*** | –   |

In the Class III group, five patients were Class III/V; in the Class IV group, four patients were Class IV/V. ***p<0.001 vs. Class II.

Table 3. The difference of renal marker proteins in two groups.

| Variables                  | Low severity (Classes I and II) (n=116) | High severity (Classes III, IV, and V) (n=71) | p  |
|----------------------------|----------------------------------------|-----------------------------------------------|----|
| Serum β2-MG (µg/ml)        | 3.49±1.33                              | 3.78±1.49                                     | 0.262 |
| Urinary β2-MG (ng/ml)      | 276±244                                | 303±225                                       | 0.517 |
| Urinary albumin (µg/ml)    | 7.08±10.07                             | 11.60±8.94                                    | 0.008**|
| Urinary IgG (µg/ml)        | 8.74±8.90                              | 13.21±9.35                                    | 0.007**|
| Urinary α1-MG (µg/ml)      | 3.03±4.94                              | 4.43±3.75                                     | 0.071 |

Data are shown as mean ±SD. **p<0.01. MG – microglobulin; IgG – immunoglobulin G.

categorized: C3, normal versus low (reference); C4, normal versus low (reference); hypertension without versus with (as reference); anti-dsDNA antibody, negative versus positive (reference); and SLEDAI, 5–9, 10–14, >15 versus 0–4 (reference). Results are reported as odds ratios (OR) with 95% confidence intervals (95% CI). Receiver operating characteristic (ROC) curve analysis, based on the multiple logistic regression model, was used to determine the diagnostic value of the protein markers. Correlations between renal marker proteins and disease activity were analyzed using the Pearson test. Two-sided \( p \) values <0.05 were considered significant.

Results

Histological features

The histopathological assessments characteristics of the lesions according to the 2003 ISN/RPS LN classification [4] are presented in Table 2. The most frequent type of histological renal lesion was mesangial proliferative glomerulonephritis (Class II, n=111, 59.7%) followed by diffuse proliferative glomerulonephritis (Class IV, n=32, 17.2%), focal segmental proliferative glomerulonephritis (Class III, n=30, 16.1%), and membranous glomerulonephritis (Class V, n=9, 4.8%) (Table 2). In the Class III group, five patients were Class III/V; in the Class IV group, four patients were Class IV/V. The mean CI was 2.10±1.66 (range 0–9). The AIs were different among the classes of disease (\( p<0.001 \)). Regarding the CI, significant differences were found between Classes II and III, Classes II and IV, and Classes II and V (\( p<0.001 \)). However, there was no difference in CI between Classes III, IV, and V (\( p>0.05 \)) (Table 2).

Characteristics of the patients

As shown in Table 1, when comparing the low and high severity groups, there was no difference between the two groups for the female/male ratio, onset age, disease duration, and time between onset of symptoms and LN diagnosis. The time between LN onset and biopsy in the high severity group was longer than in the low severity group (8.0±23.6 versus 20.5±33.2 months, \( p<0.022 \)). Compared with the low severity group, more patients in the high severity group showed fever (62.0% versus 46.6%, \( p<0.04 \)), thrombocytopenia (36.6% versus 17.2%, \( p<0.003 \)), and hypertension (28.2% versus 10.3%, \( p<0.002 \)). No significant difference was observed among the other clinical features. As expected, SLEDAI was higher in the high severity group than in the low severity group (12.5±6.6 versus 7.7±6.5, \( p<0.001 \)). There was no difference in medication prior to admission between the two groups (\( p=0.64 \) for prednisolone, \( p=0.17 \) for hydroxychloroquine, and \( p=0.88 \) for immunosuppressive agents).

Laboratory data are presented in Table 1. All patients had stable serum creatinine levels (<1.5 mg/dL). A higher proportion of patients in the high severity group had low levels of C3 (83.1% versus 50.9%, \( p<0.001 \)), low C4 (71.8% versus 53.4%, \( p=0.014 \)), and positive anti-dsDNA antibodies (59.2% versus 40.5%, \( p=0.016 \)). However, positive anti-RNP antibodies were present in a higher proportion of patients in the low severity group (44.8% versus 29.6%, \( p=0.038 \)). The proportions of
patients with positive ANA, anti-Sm antibodies, and anti-nucleosome antibodies were not significantly different between the two groups.

**Relationship between renal marker proteins and renal LN histopathology**

Compared with the low severity group, patients in the high severity group had higher UAL (11.60±8.94 versus 7.08±10.07 µg/mL, \(p=0.008\)) and urinary IgG (13.21±9.35 versus 8.74±8.90 µg/mL, \(p=0.007\)) levels (Table 3). There was no difference in serum \(\beta_2\)-MG, urinary \(\beta_2\)-MG, and urinary \(\alpha_1\)-MG levels between the two groups.

**Multivariate analysis of the renal marker proteins associated with severe renal lesions according to histologic classification of kidney biopsies**

For the multivariate analysis, the histologic classification of kidney biopsies (Classes I and II versus Classes III, IV, and V) was set as the dependent variable, and independent variables were low C3, low C4, UAL, urinary IgG, hypertension, anti-dsDNA antibody, and SLEDAI. Results showed that UAL (OR=1.417, 95% CI: 1.145–1.895, \(p=0.001\)) and SLEDAI (OR=2.004, 95% CI: 1.264–3.178, \(p=0.003\)) were independently associated with severe renal lesions in patients with LN and little or no proteinuria (Table 4). Therefore, the risk of severe renal damage increased by 1.42-fold for each increase of 1 µg/mL UAL, and increased by 2.00-fold for each categorical increase of SLEDAI.

**ROC curve analysis**

Figure 1 presents the ROC curve of UAL based on multivariate conditional logistic regression analysis. The AUC was 0.787 (\(p<0.001\)). The optimal cutoff point of UAL was 7.53 µg/mL, and the sensitivity and specificity were 67% and 82%, respectively, for the detection of high severity (Class III, IV, or V) renal lesions.

**Correlations between renal marker proteins and disease activity**

Table 5 shows that serum \(\beta_2\)-MG, urinary \(\beta_2\)-MG, UAL, urinary IgG, and urinary \(\alpha_1\)-MG were all correlated with SLEDAI (all \(p<0.01\)), while only UAL (\(r=0.24, p=0.01\)) and urinary IgG (\(r=0.20, p=0.03\)) were correlated with renal biopsy AI. None of these parameters were correlated with renal biopsy CI.

**Discussion**

The results of this study show that urinary albumin levels and SLEDAI were independently associated with histological severity of renal lesions in patients with LN and little or no proteinuria. These parameters could be used to help select patients for renal biopsy.

Some patients with SLE show evidence of nephritis on renal biopsy despite normal urinary findings and renal function, which is called silent LN (SLN) [15,31]. Although histological renal lesions in patients with SLN are usually mild (i.e.,

| Variable     | OR    | 95% CI for OR | \(p\)  |
|--------------|-------|---------------|-------|
| Urinary albumin | 1.417 | 1.145–1.895   | 0.001 |
| SLEDAI       | 2.004 | 1.264–3.178   | 0.003 |

OR = odds ratio; CI = confidence interval; SLEDAI = systemic lupus erythematosus disease activity index.
Table 5. Correlation between renal marker proteins and disease activity in LN patients with little or no proteinuria.

| Variable            | SLEDAI | Renal biopsy AI | Renal biopsy CI |
|---------------------|--------|-----------------|-----------------|
|                     | r      | p               | r               | p               | r               | p               |
| Serum β2-MG (µg/ml) | 0.317  | 0.005           | 0.136           | 0.156           | 0.032           | 0.741           |
| Urinary β2-MG (ng/ml) | 0.401  | <0.001          | 0.086           | 0.367           | ~0.057          | 0.546           |
| Urinary albumin (µg/ml) | 0.374  | 0.001           | 0.242           | 0.010           | 0.116           | 0.223           |
| Urinary IgG (µg/ml) | 0.396  | <0.001          | 0.204           | 0.031           | 0.002           | 0.985           |
| Urinary α1-MG (µg/ml) | 0.349  | 0.002           | 0.173           | 0.069           | 0.135           | 0.159           |

MG – macroglobulin; IgG – immunoglobulin G; SLEDAI – systemic lupus erythematosus disease activity index; AI – activity index; CI – chronicity index.

Class II), diffuse proliferative glomerulonephritis histological changes (Class III or IV), which are related to poor outcomes, could also be present. Zabaleta-Lanz et al. reviewed the literature and reported that 59.8% (122/204) of patients with SLN were ISN/RPS Classes I and II, while 36% were Class III or IV (16% and 20%, respectively) [16]. Wakasugi et al. also reported that 15% of patients with SLE without clinical renal involvement had Classes III and IV LN [32]. In the present study, many patients may have had SLN. On the other hand, prior to admission, some patients had an irregular treatment history of hydroxychloroquine, prednisolone, or immunosuppressive agents that could induce a clinical partial remission to some extent. As shown in Table 1, about 60% of patients had received prednisolone (mostly irregular or discontinuous) and some of them had received immunosuppressive drugs before renal biopsy, which may mask the manifestations of severe nephritis in the early stage.

Disease status was determined using SLEDAI [29] and patients with a SLEDAI >10 were considered to have highly active disease. SLEDAI assigns a weighted score for each of the clinical manifestations of SLE and therefore represents the disease activity of SLE [29,33]. SLEDAI has been shown to be associated with the presence of active LN in some studies [34,35]. In the present study, SLEDAI was independently associated with the severity of kidney lesions in patients with LN and little or no proteinuria. These results are supported by previous studies [36–38].

Proteins of high molecular weight such as IgG (150 kD) are excreted in large quantities when permeselectivity of the glomerular capillary wall is more severely disrupted, while proteins of low molecular weight such as α1-MG, β2-MG, or albumin are excreted in large quantities when proximal tubular cells lose their capacity to reabsorb them completely from the tubular lumen [19]. It was found that the urinary excretion of IgG, α1-MG, β2-MG, and albumin may be more sensitive and reliable markers than overall proteinuria for the early detection of renal involvement in some chronic diseases like diabetes mellitus [19,39–41]. Some studies showed that in patients with glomerular diseases, the urinary excretion of these marker proteins correlated with histologic lesion severity and may more efficiently predict proteinuria quantity, natural disease course, disease outcome, and treatment response [42,43]. Results of the present study suggest that albumin and IgG urinary excretions had a significant relationship with renal histological lesion severity in patients with LN and little or no proteinuria, but only UAL levels were independently associated with renal histological lesion severity in patients with LN and had a good predictive value. These results are supported by previous studies. Indeed, Miranda et al. [44] showed that UAL was associated with the presence of lupus glomerulonephritis (Class II LN). Sui et al. [45] showed that lower serum albumin levels were associated with lesion severity in patients with LN; since serum albumin levels are determined both by liver synthesis and by kidney excretion, this decrease might be due, at least in part, by increased urinary excretion. A deeper investigation of these markers during remission and progression phases, and their relationship to therapeutic response during follow-up, would provide more predictive information.

The correlation analyses revealed that the SLEDAI score was correlated with serum β2-MG, urinary β2-MG, UAL, urinary IgG, and urinary α1-MG. Indeed, the present study, as well as previous studies, revealed that these are markers of kidney damage in a number of pathologies [19,39–43]. As a score representing SLE activity, SLEDAI was associated with these markers.

Of course, many novel promising biomarkers have been evaluated in the studies of LN – for example chemokines, neutrophil gelatinase-associated lipocalin (NGAL), transferrin (TF), and α1-acid-glycoprotein (AGP) [38,46–49]. Currently, however, none has yet been rigorously validated in large-scale longitudinal cohorts of patients with different ethnic backgrounds. Compared with these new biomarkers, the renal marker proteins that were examined in the present study (serum β2-MG,....
usually treated at the Nephrology Department. In addition, one of the main symptoms was fever, which is supported by other Chinese studies [50,51], but it was impossible to differentiate SLE-related fever from infection fever. Data for cellular components in urine samples were not obtained by manual microscopy, but using an automated analysis of urinary sediment by flow cytometry, which may introduce some bias. Other markers such as the urinary albumin/creatinine ratio could be explored, but this parameter was not measured during the study period (2005–2010) and it requires repeated measurements, which is impractical in the economic context of China. Finally, only a limited panel of biomarkers was assessed, and additional markers could be explored, such as tumor necrosis factor α (TNF-α), TNF-α soluble receptor p75, and interleukin (IL)-6 [52]. Of course, many novel promising biomarkers have been evaluated in the studies of LN, such as neutrophil gelatinase-associated lipocalin (NGAL), transferrin (TF), and α1-acid-glycoprotein (AGP) [38,46–49]. Additional studies are necessary to explore these markers and to determine the best ones in predicting kidney damage in LN with low or no proteinuria. Large multicenter prospective studies are needed to investigate LN and its correlation to urine biomarkers and clinical markers like serum complements and auto-antibodies.

**Conclusions**

UAL and SLEDAI are independently associated with renal histological lesion severity. These parameters could be used to help identify patients needing a renal biopsy.

**Conflicts of interest**

The authors declare that they have no conflicts of interest.

**References:**

1. Bastian HM, Roseman JM, McGwin G Jr. et al: Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus, 2002;11: 152–60
2. Seligman VA, Lum RF, Olson JL et al: Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med, 2002; 112: 726–29
3. Li LS, Liu ZH: Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies. Kidney Int, 2004; 66: 920–23
4. Weening JJ, D’Agati VD, Schwartz MM et al: The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int, 2004; 65: 521–30
5. Christopher-Stine L, Siedner M, Lin J et al: Renal biopsy in lupus patients with low levels of proteinuria. J Rheumatol, 2007; 34: 332–35
6. Ortega LM, Schultz DR, Lenz O et al: Review: Lupus nephritis: Pathologic features, epidemiology and a guide to therapeutic decisions. Lupus, 2010; 19: 557–74
7. Austin HA: Clinical evaluation and monitoring of lupus kidney disease. Lupus, 1996; 7: 618–21
8. Nossent JC, Henzen-Logmans SC, Vroom TM et al: Relation between serological data at the time of biopsy and renal histology in lupus nephritis. Rheumatol Int, 1991; 11: 77–82
9. Gupta R, Yadav A, Misra R, Aggarwal A: Urinary prostaglandin D synthase as biomarker in lupus nephritis: a longitudinal study. Clin Exp Rheumatol, 2015; 33: 694–98
10. Watson L, Beresford MW: Urine biomarkers in juvenile-onset SLE nephritis. Pediatr Nephrol, 2013; 28: 363–74
11. Siedner MJ, Gelber AC, Rovin BH et al: Diagnostic accuracy study of urine dipstick in relation to 24-hour measurement as a screening tool for proteinuria in lupus nephritis. J Rheumatol, 2008; 35: 84–90
12. Siedner MJ, Christopher-Stine L, Astor BC et al: Screening for proteinuria in patients with lupus: A survey of practice preferences among American rheumatologists. J Rheumatol, 2007; 34: 973–77
13. Guo Q, Lu X, Xiao L et al: Analysis of clinical manifestations and pathology of lupus nephritis: A retrospective review of 82 cases. Clin Rheumatol, 2010; 29: 1175–80
14. Molino C, Fabbian F, Longhini C: Clinical approach to lupus nephritis: recent advances. Eur J Intern Med, 2009; 20: 447–53
15. Zabaleta-Lanz M, Vargas-Arenas RE, Tapanes F et al: Silent nephritis in systemic lupus erythematosus. Lupus, 2005; 12: 26–30
16. Zabaleta-Lanz ME, Munoz LE, Tapanes FI et al: Further description of early clinically silent lupus nephritis. Lupus, 2006; 15: 845–51
17. Tofik R, Aziz R, Reda A et al: The value of IgG-uria in predicting renal failure in idiopathic glomerular diseases. A long-term follow-up study. Scand J Clin Lab Invest, 2011; 71: 123–28

18. Narita T, Hosoba M, Kakei M, Ito S: Increased urinary excretions of immunglobulin g, ceruloplasmin, and transferrin predict development of microalbuminuria in patients with type 2 diabetes. Diabetes Care, 2006; 29: 142–44

19. Bazzi C, Petrcni R, Rizza V et al: Urinary excretion of IgG and alpha(1)-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy. Am J Kidney Dis, 2001; 38: 240–48

20. Choe JY, Park SH, Kim SK: Urine beta2-microglobulin is associated with clinical disease activity and renal involvement in female patients with systemic lupus erythematosus. Lupus, 2014; 23: 1486–93

21. Kim HA, Jeon JY, Yoon JM, Suh CH: Beta 2-microglobulin can be a disease activity marker in systemic lupus erythematosus. Am J Med Sci, 2010; 339: 337–40

22. Batlle-Gualda E, Martinez AC, Guerra RA, Pascual E: Urinary albumin excretion in patients with systemic lupus erythematosus without renal disease. Ann Rheum Dis, 1997; 56: 386–89

23. Varghese SA, Powell TB, Budisavljevic MN et al: Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol, 2007; 18: 913–22

24. Olsson MG, Allhorn M, Larsson J et al: Up-regulation of A1M/alpha1-microglobulin in skin by heme and reactive oxygen species gives protection from oxidative damage. PLoS One, 2011; 6: e27505

25. Gussow D, Rein R, Ginjaar I et al: The human beta 2-microglobulin gene. Primary structure and definition of the transcriptional unit. J Immunol, 1987; 139: 3132–38

26. Tan EM, Cohen AS, Fries JF et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 1982; 25: 1271–77

27. Mortensen ES, Fenton KA, Rekvig OP: Lupus nephritis: the central role of nucleosomes revealed. Am J Pathol, 2008; 172: 275–83

28. Balow JE: Clinical presentation and monitoring of lupus nephritis. Lupus, 2005; 14: 25–30

29. Bombardier C, Gladman DD, Urowitz MB et al: Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992; 35: 630–40

30. Austen KF, Muenz LR, Joyce KM et al: Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int, 1984; 25: 689-95.

31. Gonzalez-Crespo MR, Lopez-Fernandez JI, Usera G et al: Outcome of silent lupus nephritis. Semin Arthritis Rheum, 1996; 26: 468–76.

32. Wakasugi D, Gono T, Kawaguchi Y et al: Frequency of class III and IV nephritis in patients with lupus nephritis. Rheumatology (Oxford), 2006; 45: 951–57

33. Singh RG, Usha, Rathore SS et al: Urinary MCP-1 as diagnostic and prognostic marker in patients with lupus nephritis flare. Lupus, 2012; 21: 1214–18

34. Houssiau FA, D‘Cruz D, Sangle S et al: Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis. Results from the MAINTAIN Nephritis Trial. Ann Rheum Dis, 2010; 69: 2083–89

35. Chan RW, Lai FM, Li EK et al: Imbalance of Th1/Th2 transcription factors in patients with lupus nephritis. Rheumatology (Oxford), 2006; 45: 951–57

36. Singh RG, Usha, Rathore SS et al: Urinary MCP-1 as diagnostic and prognostic marker in patients with lupus nephritis flare. Lupus, 2012; 21: 1214–18

37. Chan RW, Lai FM, Li EK et al: Expression of chemokine and fibrosing factor messenger RNA in the urinary sediment of patients with lupus nephritis. Arthritis Rheum, 2004; 50: 2882–90

38. Rovin BH, Song H, Birmingham DJ et al: Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol, 2005; 16: 467–73

39. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med, 1984; 310: 356–60

40. Cono A, Zappasodi P, Pascutto C et al: Urinary proteins in multiple myeloma: Correlation with clinical parameters and diagnostic implications. Ann Hematol, 2003; 82: 487–91

41. Ottiger C, Savoca R, Yurtsever H, Huber AR: Increased sensitivity in detecting renal impairments by quantitative measurement of marker protein excretion compared to detection of pathological particles in urine sediment analysis. Clin Chem Lab Med, 2006; 44: 1347–54

42. D‘Amico G, Bazzi C: Pathophysiology of proteinuria. Kidney Int, 2003; 63: 809–25

43. D‘Amico G, Bazzi C: Urinary protein and enzyme excretion as markers of tubular damage. Curr Opin Nephrol Hypertens, 2003; 12: 639–43

44. Miranda JM, Prieto RE, Paniagua R et al: Clinical significance of serum and urine prolactin levels in lupus glomerulonephritis. Lupus, 1998; 7: 387–91

45. Sui M, Jia X, Yu C et al: Relationship between hypoalbuminemia, hyperlipidemia and renal severity in patients with lupus nephritis: A prospective study. Cent Eur J Immunol, 2014; 39: 243–52

46. Li Y, Tucci M, Narain S et al: Urinary biomarkers in lupus nephritis. Autoimmun Rev, 2006; 5: 383–88

47. Suzuki M, Wiers K, Brooks EB et al: Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis. Pediatr Res, 2009; 63: 403–12

48. Mok CC: Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol, 2010; 2010: 638413

49. Suzuki M, Wiers K, Brooks EB et al: Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis. Pediatr Nephrol, 2008; 23: 403–12

50. Li M, Zhang W, Leng X et al: Chinese SLE Treatment and Research group (CSTAR) registry: l. Major clinical characteristics of Chinese patients with systemic lupus erythematosus. Lupus, 2013; 22: 1192–99

51. Zhang S, Su J, Li X et al: Chinese SLE Treatment and Research group (CSTAR) registry: v. gender impact on Chinese patients with systemic lupus erythematosus. Lupus, 2015; 24: 1267–75.

52. Tesař V, Jiříš M Jr., Zima T et al: Soluble cytokine receptors in renal vascu-
litis and lupus nephritis. Clin Exp Immunol, 2002; 135: BR24–29